Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 1 35 versus ELIFEMME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 1 35 versus ELIFEMME.
CYCLAFEM 1/35 vs ELIFEMME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
Elifemme is a small-molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD4. It disrupts the interaction between BET proteins and acetylated histones, thereby inhibiting oncogene transcription including MYC and BCL2.
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
Subcutaneous injection: 0.5 mL (15 mg) once weekly.
None Documented
None Documented
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Terminal elimination half-life is 24-30 hours, allowing once-daily dosing for treatment of relapsed/refractory multiple myeloma.
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Primarily unchanged in feces (approx. 60-70%) via biliary excretion, with renal excretion accounting for <10% of the dose.
Category C
Category C
Oral Contraceptive
Oral Contraceptive